ArticleAntimicrobial agents and chemotherapy2004
PnuC and the utilization of the nicotinamide riboside analog 3-aminopyridine in Haemophilus influenzae.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Virulence and genome analysis of three historicalFrontiers in cellular and infection microbiology · 2025Article
- Exogenous methionine contributes to reversing the resistance ofMicrobiology spectrum · 2024Article
- Biosynthesis of β-nicotinamide mononucleotide from glucose via a new pathway inFrontiers in microbiology · 2024Article
- Oral supplementation of nicotinamide riboside alters intestinal microbial composition in rats and mice, but not humans.npj aging · 2023Article
- Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer's mouse model.Frontiers in aging neuroscience · 2022Article
- Comprehensive discovery of novel structured noncoding RNAs in 26 bacterial genomes.RNA biology · 2021Article
- Metabolic engineering of Escherichia coli for biosynthesis of β-nicotinamide mononucleotide from nicotinamide.Microbial biotechnology · 2021Article
- A second riboswitch class for the enzyme cofactor NADRNA (New York, N.Y.) · 2021Article
- Metabolic engineering of Escherichia coli for optimized biosynthesis of nicotinamide mononucleotide, a noncanonical redox cofactor.Microbial cell factories · 2020Article
- Structural and Functional Characterization of NadR fromMolecules (Basel, Switzerland) · 2020Article
- Niacin-mediated Gene Expression and Role of NiaR as a Transcriptional Repressor ofFrontiers in cellular and infection microbiology · 2017Article
- Functional mining of transporters using synthetic selections.Nature chemical biology · 2016Article
- Whole genomic sequence analysis of Bacillus infantis: defining the genetic blueprint of strain NRRL B-14911, an emerging cardiopathogenic microbe.BMC genomics · 2016Article
- Characterization of NAD salvage pathways and their role in virulence in Streptococcus pneumoniae.Microbiology (Reading, England) · 2015Article
- Crystal structure of the vitamin B3 transporter PnuC, a full-length SWEET homolog.Nature structural & molecular biology · 2014Article
- Outer membrane protein P4 is not required for virulence in the human challenge model of Haemophilus ducreyi infection.BMC microbiology · 2014Article
- Article
- Characterization of riboflavin (vitamin B2) transport proteins from Bacillus subtilis and Corynebacterium glutamicum.Journal of bacteriology · 2007Article
- NAD+ utilization in Pasteurellaceae: simplification of a complex pathway.Journal of bacteriology · 2006Review
- Assimilation of nicotinamide mononucleotide requires periplasmic AphA phosphatase in Salmonella enterica.Journal of bacteriology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The utilization pathway for the uptake of NAD and nicotinamide riboside was previously characterized for Haemophilus influenzae. We now report on the cellular location, topology, and substrate specificity of PnuC. pnuC of H. influenzae is only distantly related to pnuC of Escherichia coli and Salmonella enterica serovar Typhimurium. When E. coli PnuC was expressed in an H. influenzae pnuC mutant, it was able to take up only nicotinamide riboside and not nicotinamide mononucleotide. Therefore, we postulated that PnuC transporters in general possess specificity for nicotinamide riboside. Earlier studies showed that 3-aminopyridine derivatives (e.g., 3-aminopyridine adenine dinucleotide) are inhibitory for H. influenzae growth. By testing characterized strains with mutations in the NAD utilization pathway, we show that 3-aminopyridine riboside is inhibitory to H. influenzae and is taken up by the NAD-processing and nicotinamide riboside route. 3-Aminopyridine riboside is utilized effectively in a pnuC+ background. In addition, we demonstrate that 3-aminopyridine adenine dinucleotide resynthesis is produced by NadR. 3-Aminopyridine riboside-resistant H. influenzae isolates were characterized, and mutations in nadR could be detected. We also tested other species of the family Pasteurellaceae, Pasteurella multocida and Actinobacillus actinomycetemcomitans, and found that 3-aminopyridine riboside does not act as a growth inhibitor; hence, 3-aminopyridine riboside represents an anti-infective agent with a very narrow host range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.